NT-I7 (efineptakin alfa)
Solid Tumors (combo with anti-PD-1)
Key Facts
About NeoImmuneTech
NeoImmuneTech is a private, pre-revenue biotech developing innovative immunotherapies based on T-cell homeostasis. Its lead asset, NT-I7 (efineptakin alfa), is a long-acting human interleukin-7 (IL-7) designed to expand and enhance T-cell populations, with multiple Phase 1b/2 trials ongoing in oncology and as a vaccine adjuvant. The company's strategy involves advancing NT-I7 both as a monotherapy and in combination with other modalities like checkpoint inhibitors, chemotherapy, and cellular therapies to address significant unmet needs in immuno-oncology and infectious diseases.
View full company profileAbout NeoImmuneTech
NeoImmuneTech is a private, pre-revenue biotech developing innovative immunotherapies based on T-cell homeostasis. Its lead asset, NT-I7 (efineptakin alfa), is a long-acting human interleukin-7 (IL-7) designed to expand and enhance T-cell populations, with multiple Phase 1b/2 trials ongoing in oncology and as a vaccine adjuvant. The company's strategy involves advancing NT-I7 both as a monotherapy and in combination with other modalities like checkpoint inhibitors, chemotherapy, and cellular therapies to address significant unmet needs in immuno-oncology and infectious diseases.
View full company profileAbout NeoImmuneTech
NeoImmuneTech is a private, pre-revenue biotech developing innovative immunotherapies based on T-cell homeostasis. Its lead asset, NT-I7 (efineptakin alfa), is a long-acting human interleukin-7 (IL-7) designed to expand and enhance T-cell populations, with multiple Phase 1b/2 trials ongoing in oncology and as a vaccine adjuvant. The company's strategy involves advancing NT-I7 both as a monotherapy and in combination with other modalities like checkpoint inhibitors, chemotherapy, and cellular therapies to address significant unmet needs in immuno-oncology and infectious diseases.
View full company profile